Rituximab with alkylating agent in anti‐myelin‐associated glycoprotein neuropathy: A retrospective study of 26 cases

British Journal of HaematologyEarly View LETTER TO THE EDITOR Rituximab with alkylating agent in anti-myelin-associated glycoprotein neuropathy: A retrospective study of 26 cases D. Elessa, D. Elessa orcid.org/0000-0003-0926-4611 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorV. Grosjean, V. Grosjean Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorP. Lozeron, P. Lozeron Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorS. Harel, S. Harel Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorB. Royer, B. Royer Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorN. Forgeard, N. Forgeard orcid.org/0000-0001-8381-2773 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorF. Thèves, F. Thèves orcid.org/0000-0002-3816-1825 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorA. Talbot, A. Talbot DrAlexisTalbot Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorM. Malphettes, M. Malphettes orcid.org/0000-0002-9888-2528 Université Paris Cité, Paris, France Service d'Immuno-pathologie Clinique, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, FranceSearch for more papers by this authorD. Bengoufa, D. Bengoufa Université Paris Cité, Paris, France Laboratoire d'Immunologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, FranceSearch for more papers by this authorN. Kubis, N. Kubis Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorB. Arnulf, Corresponding Author B. Arnulf [email protected] orcid.org/0000-0001-7719-3611 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, France Correspondence B. Arnulf, Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Email: [email protected]Search for more papers by this author D. Elessa, D. Elessa orcid.org/0000-0003-0926-4611 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorV. Grosjean, V. Grosjean Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorP. Lozeron, P. Lozeron Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorS. Harel, S. Harel Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorB. Royer, B. Royer Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorN. Forgeard, N. Forgeard orcid.org/0000-0001-8381-2773 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorF. Thèves, F. Thèves orcid.org/0000-0002-3816-1825 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorA. Talbot, A. Talbot DrAlexisTalbot Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, FranceSearch for more papers by this authorM. Malphettes, M. Malphettes orcid.org/0000-0002-9888-2528 Université Paris Cité, Paris, France Service d'Immuno-pathologie Clinique, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, FranceSearch for more papers by this authorD. Bengoufa, D. Bengoufa Université Paris Cité, Paris, France Laboratoire d'Immunologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, FranceSearch for more papers by this authorN. Kubis, N. Kubis Université Paris Cité, Paris, France Service de Physiologie Clinique-Explorations Fonctionnelles, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Paris, FranceSearch for more papers by this authorB. Arnulf, Corresponding Author B. Arnulf [email protected] orcid.org/0000-0001-7719-3611 Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, Paris, France Université Paris Cité, Paris, France Correspondence B. Arnulf, Service d'Immuno-Hématologie, Assistance Publique – Hôpitaux de Paris, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Email: [email protected]Search for more papers by this author First published: 18 March 2024 https://doi.org/10.1111/bjh.19412 D. Elessa and V. Grosjean participated equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Supporting Information Filename Description bjh19412-sup-0001-AppendixS1.docxWord 2007 document , 32.6 KB Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Steck AJ. Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol. 2021; 361:577725. https://doi.org/10.1016/j.jneuroim.2021.577725 10.1016/j.jneuroim.2021.577725 CASPubMedWeb of Science®Google Scholar 2Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009; 65(3): 286–293. https://doi.org/10.1002/ana.21577 10.1002/ana.21577 CASPubMedWeb of Science®Google Scholar 3Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013; 80(24): 2217–2225. https://doi.org/10.1212/WNL.0b013e318296e92b 10.1212/WNL.0b013e318296e92b CASPubMedWeb of Science®Google Scholar 4Nivet T, Baptiste A, Belin L, Ghillani-Dalbin P, Algrin C, Choquet S, et al. Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: a report of 64 patients. Br J Haematol. 2022; 198(2): 298–306. https://doi.org/10.1111/bjh.18202 10.1111/bjh.18202 CASPubMedWeb of Science®Google Scholar 5Tang MAH, Mathis S, Duffau P, Cazenave P, Solé G, Duval F, et al. Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. J Neurol. 2020; 267(2): 561–571. https://doi.org/10.1007/s00415-019-09618-0 10.1007/s00415-019-09618-0 CASPubMedWeb of Science®Google Scholar 6Galassi G, Tondelli M, Ariatti A, Benuzzi F, Nichelli P, Valzania F. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int J Neurosci. 2017; 127(5): 439–447. https://doi.org/10.1080/00207454.2016.1191013 10.1080/00207454.2016.1191013 CASPubMedWeb of Science®Google Scholar 7Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017; 35(17): 1905–1912. https://doi.org/10.1200/JCO.2016.70.6994 10.1200/JCO.2016.70.6994 CASPubMedWeb of Science®Google Scholar 8Hughes R, Bensa S, Willison H, van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50(2): 195–201. https://doi.org/10.1002/ana.1088 10.1002/ana.1088 CASPubMedWeb of Science®Google Scholar 9Baron M, Lozeron P, Harel S, Bengoufa D, Vignon M, Asli B, et al. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. J Neurol. 2017; 264(6): 1132–1135. https://doi.org/10.1007/s00415-017-8502-3 10.1007/s00415-017-8502-3 CASPubMedWeb of Science®Google Scholar 10Planche V. Heavy/light chain ratio as a biomarker for monitoring patients with IgM monoclonal gammopathy and anti-MAG neuropathy. J Hematol Thromboembolic Dis. 2014; 2(3):142. https://doi.org/10.4172/2329-8790.1000142 10.4172/2329?8790.1000142 Google Scholar 11Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain J Neurol. 2000; 123(Pt 4): 710–717. https://doi.org/10.1093/brain/123.4.710 10.1093/brain/123.4.710 PubMedWeb of Science®Google Scholar 12Hänggi P, Aliu B, Martin K, Herrendorff R, Steck AJ. Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy: retrospective study. Neurol Neuroimmunol Neuroinflamm. 2022; 9(1):e1109. https://doi.org/10.1212/NXI.0000000000001109 10.1212/NXI.0000000000001109 PubMedWeb of Science®Google Scholar 13Vallat JM, Jauberteau MO, Bordessoule D, Yardin C, Preux PM, Couratier P. Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases. J Neurol Sci. 1996; 137(2): 124–130. https://doi.org/10.1016/0022-510x(95)00343-z 10.1016/0022-510X(95)00343-Z CASPubMedWeb of Science®Google Scholar 14Iancu Ferfoglia R, Guimarães-Costa R, Viala K, Musset L, Neil J, Marin B, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016; 21(1): 10–14. https://doi.org/10.1111/jns.12156 10.1111/jns.12156 CASPubMedWeb of Science®Google Scholar 15Castellani F, Visentin A, Campagnolo M, Salvalaggio A, Cacciavillani M, Candiotto C, et al. The bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm. 2020; 7(4):e720. https://doi.org/10.1212/NXI.0000000000000720 10.1212/NXI.0000000000000720 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation